New data shows fenebrutinib delays disability progression in primary progressive MS, especially preserving arm function, with a comparable safety profile to ocrelizumab.
A new Australian study found pain is more common in people with MS than in the general population. It describes the lived experience of different types of pain and how they occur in different proportions and severity and differ by MS type, guiding towards better management.
The phase 3 clinical trial of tolebrutinib did not delay disability progression in people with primary progressive MS, and it has not been approved in the USA for non-relapsing secondary progressive MS.
People with relapsing remitting MS can now access injectable Ocrevus® (ocrelizumab) through the Pharmaceutical Benefits Scheme.
An online training program helps healthcare providers feel more confident and skilled in delivering exercise program to people with MS.
Fenebrutinib is a new treatment from the BTK inhibitor class, which aims to target immune cells throughout the body including the brain and spinal cord to treat MS.
